Celularity shares more than doubled after MuseCell Innovations outlined a potentially large U.S. manufacturing relationship. The stock traded at $1.94 around midday, up 120.4%.
| Facility | 147,215 sq. ft. |
| Grade C / ISO 7 suites | 9 |
| Grade D / ISO 8 suites | 6 |
| Products in scope | MuseCells, exosomes, secretome |
| Potential jobs | >200, non-binding |
| Measure | Latest disclosed |
|---|---|
| 2025 revenue | $26.6M |
| 2025 net loss | -$91.7M |
| Year-end cash | $6.2M |
| Accumulated deficit | $991.5M |
| Potential annualized purchases | >$60M |
| Ticker | Price | Day | Market value |
|---|---|---|---|
| CELU | $1.94 | +120.4% | $51.4M |
| LGVN | $6.73 | -4.3% | $211.2M |
| DYAI | $0.65 | -1.2% | $23.8M |
| MRKR | $1.48 | +2.1% | $28.0M |
| Stage | Evidence investors need | Risk |
|---|---|---|
| Initial project | Technology transfer and qualified process | Yield, comparability and release criteria |
| Expansion | Binding purchase orders and production volumes | $300M estimate may not convert |
| Cash flow | Revenue collection and margin disclosure | Financing and dilution |
| Listing | Compliance plan due Sept. 4 | Two overdue Form 10-Q filings |
![Asia Stock Market Today 28/08/2026 [UPDATE: 00:51 SGT] [Salesforce Leads KASE Global Into Final Minutes After Asia’s Split Close]](https://ts2.tech/wp-content/uploads/2026/08/Asia-market-dashboard-2026-08-28-0051-480x384.jpg "Asia Stock Market Today 28/08/2026 [UPDATE: 00:51 SGT] [Salesforce Leads KASE Global Into Final Minutes After Asia’s Split Close]")
